
Ratos acquires 60% of TFS
Swedish listed GP Ratos has acquired a 60% stake in Lund-based clinical trials operator TFS Trial Form Support International, in a deal valuing the whole company at €47m.
Ratos will provide around €15m of equity, as well as an additional €12m component dependent on TFS's performance in 2015/16.
The deal sees the founder and CEO of TFS, Daniel Spasic, retain 40% of the shares and his position as CEO. The transaction is expected to be completed by the beginning of Q4 2015.
Ratos said it views the acquisition of TFS as a clear case for acquisition-led growth, with clear opportunities for international consolidation within the industry.
Company
Founded in Lund in 1996, TFS Trial Form International is a contract research organisation, which operates clinical trials for biotech, pharma and medical device companies.
The company employs 670 people across 23 offices in Europe and North America, from which it conducts trials in 40 countries. In the year to August 2015, TFS had revenues of around €49m.
People
Susanna Campbell is the CEO of Ratos. Daniel Spasic is the founder and CEO of TFS.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater